The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
metreleptin (Brand name: Myalept)
- Manufactured by
Amylin Pharmaceuticals, LLC
FDA-approved indication: Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
National Library of Medicine Drug Information Portal